job_id,status,total_refs,completed_refs,failed_refs,created_at,updated_at,references_text
41523c63-708a-4073-baf3-e862e12b33c3,completed,2,1,1,2025-08-10T21:42:06.234281,2025-08-10T21:42:23.965987,"24 Pfrommer L, Diexer S, Klee B, et al. Post-COVID Recovery is More Likely after an Infection with the SARS-CoV-2 Omicron Variant: A Population-Based Cohort Study.
25 Hampshire A, Azor A, Atchison C, et al. Cognition and Memory after Covid-19 in a Large Community Sample. N Engl J Med. 2024;390(9):806-818."
c58378cd-fe9d-4a27-94f1-698f370b4e51,failed,0,0,0,2025-08-14T08:38:05.037092,2025-08-14T08:38:32.206402,"50 United States Department of Health and Human Services and the United States Department of
Justice, Guidance on “Long COVID” as a Disability Under the ADA, Section 504, and Section
1557, https://archive.ada.gov/long_covid_joint_guidance.pdf, Accessed May 12, 2024.
51 Centers for Disease Control and Prevention. Myalgic Encephalomyelitis/Chronic Fatigue
Syndrome: Strategies to Prevent Worsening of Symptoms; 2024; accessed August 1, 2024 via

https://www.cdc.gov/me-cfs/hcp/clinical-care/treating-the-most-disruptive-symptoms-first-
and-preventing-worsening-of-symptoms.html?CDC_AAref_Val=https://www.cdc.gov/me-
cfs/healthcare-providers/clinical-care-patients-mecfs/treating-most-disruptive-symptoms.html

52 Afrin LB, Weinstock LB, Molderings GJ. Covid-19 hyperinflammation and post-Covid-19 illness
may be rooted in mast cell activation syndrome. Int J Infect Dis. 2020;100:327-332.
doi:10.1016/j.ijid.2020.09.016
53 Pollack B, von Saltza E, McCorkell L, et al. Female reproductive health impacts of Long COVID
and associated illnesses including ME/CFS, POTS, and connective tissue disorders: a literature
review. Front Rehabil Sci. 2023;4:1122673. Published 2023 Apr 28.
doi:10.3389/fresc.2023.1122673
54 Silva J, Takahashi T, Wood J, et al. Sex differences in symptomatology and immune profiles of
Long COVID. Preprint. medRxiv. 2024;2024.02.29.24303568. Published 2024 Mar 4.
doi:10.1101/2024.02.29.24303568
55 Patoulias D, Stavropoulos K, Imprialos K, et al. Inflammatory Markers in Cardiovascular Disease;
Lessons Learned and Future Perspectives. Curr Vasc Pharmacol. 2021;19(3):323-342.
doi:10.2174/1570161118666200318104434
56 Xuereb RA, Borg M, Vella K, et al. Long COVID Syndrome: A Case-Control Study. Am J Med.
Published online May 9, 2023. doi:10.1016/j.amjmed.2023.04.022.
57 Homerton University Hospital: NHS Foundation Trust. Post COVID-19 Patient information pack:
Helping you to recover and manage your symptoms following COVID-19; 2021. accessed
7/21/21 via https://www.hackneycitizen.co.uk/wp-content/uploads/Post-COVID-19-
information-pack-5.pdf
58 Parkinson MD, Stout R, Dysinger W. Lifestyle Medicine: Prevention, Treatment, and Reversal of
Disease. Med Clin North Am. 2023 Nov;107(6):1109-1120. doi: 10.1016/j.mcna.2023.06.007.
Epub 2023 Jul 16. PMID: 37806726.
59 Storz MA. Lifestyle Adjustments in Long-COVID Management: Potential Benefits of Plant-Based
Diets. Curr Nutr Rep. 2021;10(4):352-363. doi:10.1007/s13668-021-00369-x
60 O’Kelly B, Vidal L, McHugh T, Woo J, Avramovic G, Lambert JS. Safety and efficacy of low dose
naltrexone in a long covid cohort; An interventional pre-post study. Brain Behav Immun Health
(2022) 24:100485. doi: 10.1016/j.bbih.2022.100485
61 Polo O PP, Tuominen E. Low-dose naltrexone in the treatment of myalgic
encephalomyelitis/chronic fatigue syndrome (ME/CFS). In: Fatigue: Biomedicine, health &
behavior (2019) (Informa UK Limited: Taylor & Francis Group; ). doi:
10.1080/21641846.2019.1692770
62 Naik H, Cooke E, Boulter T, et al. Low-dose naltrexone for post-COVID fatigue syndrome: a study
protocol for a double-blind, randomised trial in British Columbia. BMJ Open.
2024;14(5):e085272. Published 2024 May 13. doi:10.1136/bmjopen-2024-085272
63 Arbel R, Peretz A, Sergienko R, et al. Effectiveness of a bivalent mRNA vaccine booster dose to
prevent severe COVID-19 outcomes: a retrospective cohort study. Lancet Infect Dis.
2023;23(8):914-921. doi:10.1016/S1473-3099(23)00122-6
64 Fabiani M, Mateo-Urdiales A, Sacco C, et al. Protection against severe COVID-19 after second
booster dose of adapted bivalent (original/Omicron BA.4-5) mRNA vaccine in persons ≥ 60
years, by time since infection, Italy, 12 September to 11 December 2022. Euro Surveill.
2023;28(8):2300105. doi:10.2807/1560-7917.ES.2023.28.8.2300105"
152f386a-c10c-4a87-8c36-05c4fb538599,failed,0,0,0,2025-08-14T08:38:05.877131,2025-08-14T08:38:33.948808,"50 United States Department of Health and Human Services and the United States Department of
Justice, Guidance on “Long COVID” as a Disability Under the ADA, Section 504, and Section
1557, https://archive.ada.gov/long_covid_joint_guidance.pdf, Accessed May 12, 2024.
51 Centers for Disease Control and Prevention. Myalgic Encephalomyelitis/Chronic Fatigue
Syndrome: Strategies to Prevent Worsening of Symptoms; 2024; accessed August 1, 2024 via

https://www.cdc.gov/me-cfs/hcp/clinical-care/treating-the-most-disruptive-symptoms-first-
and-preventing-worsening-of-symptoms.html?CDC_AAref_Val=https://www.cdc.gov/me-
cfs/healthcare-providers/clinical-care-patients-mecfs/treating-most-disruptive-symptoms.html

52 Afrin LB, Weinstock LB, Molderings GJ. Covid-19 hyperinflammation and post-Covid-19 illness
may be rooted in mast cell activation syndrome. Int J Infect Dis. 2020;100:327-332.
doi:10.1016/j.ijid.2020.09.016
53 Pollack B, von Saltza E, McCorkell L, et al. Female reproductive health impacts of Long COVID
and associated illnesses including ME/CFS, POTS, and connective tissue disorders: a literature
review. Front Rehabil Sci. 2023;4:1122673. Published 2023 Apr 28.
doi:10.3389/fresc.2023.1122673
54 Silva J, Takahashi T, Wood J, et al. Sex differences in symptomatology and immune profiles of
Long COVID. Preprint. medRxiv. 2024;2024.02.29.24303568. Published 2024 Mar 4.
doi:10.1101/2024.02.29.24303568
55 Patoulias D, Stavropoulos K, Imprialos K, et al. Inflammatory Markers in Cardiovascular Disease;
Lessons Learned and Future Perspectives. Curr Vasc Pharmacol. 2021;19(3):323-342.
doi:10.2174/1570161118666200318104434
56 Xuereb RA, Borg M, Vella K, et al. Long COVID Syndrome: A Case-Control Study. Am J Med.
Published online May 9, 2023. doi:10.1016/j.amjmed.2023.04.022.
57 Homerton University Hospital: NHS Foundation Trust. Post COVID-19 Patient information pack:
Helping you to recover and manage your symptoms following COVID-19; 2021. accessed
7/21/21 via https://www.hackneycitizen.co.uk/wp-content/uploads/Post-COVID-19-
information-pack-5.pdf
58 Parkinson MD, Stout R, Dysinger W. Lifestyle Medicine: Prevention, Treatment, and Reversal of
Disease. Med Clin North Am. 2023 Nov;107(6):1109-1120. doi: 10.1016/j.mcna.2023.06.007.
Epub 2023 Jul 16. PMID: 37806726.
59 Storz MA. Lifestyle Adjustments in Long-COVID Management: Potential Benefits of Plant-Based
Diets. Curr Nutr Rep. 2021;10(4):352-363. doi:10.1007/s13668-021-00369-x
60 O’Kelly B, Vidal L, McHugh T, Woo J, Avramovic G, Lambert JS. Safety and efficacy of low dose
naltrexone in a long covid cohort; An interventional pre-post study. Brain Behav Immun Health
(2022) 24:100485. doi: 10.1016/j.bbih.2022.100485
61 Polo O PP, Tuominen E. Low-dose naltrexone in the treatment of myalgic
encephalomyelitis/chronic fatigue syndrome (ME/CFS). In: Fatigue: Biomedicine, health &
behavior (2019) (Informa UK Limited: Taylor & Francis Group; ). doi:
10.1080/21641846.2019.1692770
62 Naik H, Cooke E, Boulter T, et al. Low-dose naltrexone for post-COVID fatigue syndrome: a study
protocol for a double-blind, randomised trial in British Columbia. BMJ Open.
2024;14(5):e085272. Published 2024 May 13. doi:10.1136/bmjopen-2024-085272
63 Arbel R, Peretz A, Sergienko R, et al. Effectiveness of a bivalent mRNA vaccine booster dose to
prevent severe COVID-19 outcomes: a retrospective cohort study. Lancet Infect Dis.
2023;23(8):914-921. doi:10.1016/S1473-3099(23)00122-6
64 Fabiani M, Mateo-Urdiales A, Sacco C, et al. Protection against severe COVID-19 after second
booster dose of adapted bivalent (original/Omicron BA.4-5) mRNA vaccine in persons ≥ 60
years, by time since infection, Italy, 12 September to 11 December 2022. Euro Surveill.
2023;28(8):2300105. doi:10.2807/1560-7917.ES.2023.28.8.2300105"
ae8110b8-76dc-4e93-ac03-a6747dbea0a3,failed,0,0,0,2025-08-14T08:38:23.217165,2025-08-14T08:38:50.542590,"50 United States Department of Health and Human Services and the United States Department of
Justice, Guidance on “Long COVID” as a Disability Under the ADA, Section 504, and Section
1557, https://archive.ada.gov/long_covid_joint_guidance.pdf, Accessed May 12, 2024.
51 Centers for Disease Control and Prevention. Myalgic Encephalomyelitis/Chronic Fatigue
Syndrome: Strategies to Prevent Worsening of Symptoms; 2024; accessed August 1, 2024 via

https://www.cdc.gov/me-cfs/hcp/clinical-care/treating-the-most-disruptive-symptoms-first-
and-preventing-worsening-of-symptoms.html?CDC_AAref_Val=https://www.cdc.gov/me-
cfs/healthcare-providers/clinical-care-patients-mecfs/treating-most-disruptive-symptoms.html

52 Afrin LB, Weinstock LB, Molderings GJ. Covid-19 hyperinflammation and post-Covid-19 illness
may be rooted in mast cell activation syndrome. Int J Infect Dis. 2020;100:327-332.
doi:10.1016/j.ijid.2020.09.016
53 Pollack B, von Saltza E, McCorkell L, et al. Female reproductive health impacts of Long COVID
and associated illnesses including ME/CFS, POTS, and connective tissue disorders: a literature
review. Front Rehabil Sci. 2023;4:1122673. Published 2023 Apr 28.
doi:10.3389/fresc.2023.1122673
54 Silva J, Takahashi T, Wood J, et al. Sex differences in symptomatology and immune profiles of
Long COVID. Preprint. medRxiv. 2024;2024.02.29.24303568. Published 2024 Mar 4.
doi:10.1101/2024.02.29.24303568
55 Patoulias D, Stavropoulos K, Imprialos K, et al. Inflammatory Markers in Cardiovascular Disease;
Lessons Learned and Future Perspectives. Curr Vasc Pharmacol. 2021;19(3):323-342.
doi:10.2174/1570161118666200318104434
56 Xuereb RA, Borg M, Vella K, et al. Long COVID Syndrome: A Case-Control Study. Am J Med.
Published online May 9, 2023. doi:10.1016/j.amjmed.2023.04.022.
57 Homerton University Hospital: NHS Foundation Trust. Post COVID-19 Patient information pack:
Helping you to recover and manage your symptoms following COVID-19; 2021. accessed
7/21/21 via https://www.hackneycitizen.co.uk/wp-content/uploads/Post-COVID-19-
information-pack-5.pdf
58 Parkinson MD, Stout R, Dysinger W. Lifestyle Medicine: Prevention, Treatment, and Reversal of
Disease. Med Clin North Am. 2023 Nov;107(6):1109-1120. doi: 10.1016/j.mcna.2023.06.007.
Epub 2023 Jul 16. PMID: 37806726.
59 Storz MA. Lifestyle Adjustments in Long-COVID Management: Potential Benefits of Plant-Based
Diets. Curr Nutr Rep. 2021;10(4):352-363. doi:10.1007/s13668-021-00369-x
60 O’Kelly B, Vidal L, McHugh T, Woo J, Avramovic G, Lambert JS. Safety and efficacy of low dose
naltrexone in a long covid cohort; An interventional pre-post study. Brain Behav Immun Health
(2022) 24:100485. doi: 10.1016/j.bbih.2022.100485
61 Polo O PP, Tuominen E. Low-dose naltrexone in the treatment of myalgic
encephalomyelitis/chronic fatigue syndrome (ME/CFS). In: Fatigue: Biomedicine, health &
behavior (2019) (Informa UK Limited: Taylor & Francis Group; ). doi:
10.1080/21641846.2019.1692770
62 Naik H, Cooke E, Boulter T, et al. Low-dose naltrexone for post-COVID fatigue syndrome: a study
protocol for a double-blind, randomised trial in British Columbia. BMJ Open.
2024;14(5):e085272. Published 2024 May 13. doi:10.1136/bmjopen-2024-085272
63 Arbel R, Peretz A, Sergienko R, et al. Effectiveness of a bivalent mRNA vaccine booster dose to
prevent severe COVID-19 outcomes: a retrospective cohort study. Lancet Infect Dis.
2023;23(8):914-921. doi:10.1016/S1473-3099(23)00122-6
64 Fabiani M, Mateo-Urdiales A, Sacco C, et al. Protection against severe COVID-19 after second
booster dose of adapted bivalent (original/Omicron BA.4-5) mRNA vaccine in persons ≥ 60
years, by time since infection, Italy, 12 September to 11 December 2022. Euro Surveill.
2023;28(8):2300105. doi:10.2807/1560-7917.ES.2023.28.8.2300105"
deb97c2a-10d2-4a45-9303-c9e3f3843a1f,failed,1,0,1,2025-08-14T08:43:44.530936,2025-08-14T08:43:50.664617,"United States Department of Health and Human Services and the United States Department of
Justice, Guidance on “Long COVID” as a Disability Under the ADA, Section 504, and Section
1557, https://archive.ada.gov/long_covid_joint_guidance.pdf, Accessed May 12, 2024."
477f5852-a52a-4369-888a-41074cbb9129,completed,4,3,1,2025-08-14T08:44:22.312392,2025-08-14T08:45:00.213817,"51 Centers for Disease Control and Prevention. Myalgic Encephalomyelitis/Chronic Fatigue
Syndrome: Strategies to Prevent Worsening of Symptoms; 2024; accessed August 1, 2024 via

https://www.cdc.gov/me-cfs/hcp/clinical-care/treating-the-most-disruptive-symptoms-first-
and-preventing-worsening-of-symptoms.html?CDC_AAref_Val=https://www.cdc.gov/me-
cfs/healthcare-providers/clinical-care-patients-mecfs/treating-most-disruptive-symptoms.html

52 Afrin LB, Weinstock LB, Molderings GJ. Covid-19 hyperinflammation and post-Covid-19 illness
may be rooted in mast cell activation syndrome. Int J Infect Dis. 2020;100:327-332.
doi:10.1016/j.ijid.2020.09.016
53 Pollack B, von Saltza E, McCorkell L, et al. Female reproductive health impacts of Long COVID
and associated illnesses including ME/CFS, POTS, and connective tissue disorders: a literature
review. Front Rehabil Sci. 2023;4:1122673. Published 2023 Apr 28.
doi:10.3389/fresc.2023.1122673
54 Silva J, Takahashi T, Wood J, et al. Sex differences in symptomatology and immune profiles of
Long COVID. Preprint. medRxiv. 2024;2024.02.29.24303568. Published 2024 Mar 4.
doi:10.1101/2024.02.29.24303568"
e84b7487-0146-436d-a874-23e17f1f9f03,completed,11,10,1,2025-08-14T08:45:49.390129,2025-08-14T08:47:24.612480,"55 Patoulias D, Stavropoulos K, Imprialos K, et al. Inflammatory Markers in Cardiovascular Disease;
Lessons Learned and Future Perspectives. Curr Vasc Pharmacol. 2021;19(3):323-342.
doi:10.2174/1570161118666200318104434
56 Xuereb RA, Borg M, Vella K, et al. Long COVID Syndrome: A Case-Control Study. Am J Med.
Published online May 9, 2023. doi:10.1016/j.amjmed.2023.04.022.
57 Homerton University Hospital: NHS Foundation Trust. Post COVID-19 Patient information pack:
Helping you to recover and manage your symptoms following COVID-19; 2021. accessed
7/21/21 via https://www.hackneycitizen.co.uk/wp-content/uploads/Post-COVID-19-
information-pack-5.pdf
58 Parkinson MD, Stout R, Dysinger W. Lifestyle Medicine: Prevention, Treatment, and Reversal of
Disease. Med Clin North Am. 2023 Nov;107(6):1109-1120. doi: 10.1016/j.mcna.2023.06.007.
Epub 2023 Jul 16. PMID: 37806726.
59 Storz MA. Lifestyle Adjustments in Long-COVID Management: Potential Benefits of Plant-Based
Diets. Curr Nutr Rep. 2021;10(4):352-363. doi:10.1007/s13668-021-00369-x
60 O’Kelly B, Vidal L, McHugh T, Woo J, Avramovic G, Lambert JS. Safety and efficacy of low dose
naltrexone in a long covid cohort; An interventional pre-post study. Brain Behav Immun Health
(2022) 24:100485. doi: 10.1016/j.bbih.2022.100485
61 Polo O PP, Tuominen E. Low-dose naltrexone in the treatment of myalgic
encephalomyelitis/chronic fatigue syndrome (ME/CFS). In: Fatigue: Biomedicine, health &
behavior (2019) (Informa UK Limited: Taylor & Francis Group; ). doi:
10.1080/21641846.2019.1692770
62 Naik H, Cooke E, Boulter T, et al. Low-dose naltrexone for post-COVID fatigue syndrome: a study
protocol for a double-blind, randomised trial in British Columbia. BMJ Open.
2024;14(5):e085272. Published 2024 May 13. doi:10.1136/bmjopen-2024-085272
63 Arbel R, Peretz A, Sergienko R, et al. Effectiveness of a bivalent mRNA vaccine booster dose to
prevent severe COVID-19 outcomes: a retrospective cohort study. Lancet Infect Dis.
2023;23(8):914-921. doi:10.1016/S1473-3099(23)00122-6
64 Fabiani M, Mateo-Urdiales A, Sacco C, et al. Protection against severe COVID-19 after second
booster dose of adapted bivalent (original/Omicron BA.4-5) mRNA vaccine in persons ≥ 60
years, by time since infection, Italy, 12 September to 11 December 2022. Euro Surveill.
2023;28(8):2300105. doi:10.2807/1560-7917.ES.2023.28.8.2300105
65 Tenforde MW, Weber ZA, Natarajan K, et al. Early Estimates of Bivalent mRNA Vaccine
Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care

Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine
States, September-November 2022 [published correction appears in MMWR Morb Mortal Wkly
Rep. 2023 Mar 17;72(11):292. doi: 10.15585/mmwr.mm7211a6]. MMWR Morb Mortal Wkly
Rep. 2022;71(5152):1616-1624. Published 2022 Dec 30. doi:10.15585/mmwr.mm715152e1"
961faa71-b031-4ca6-8a64-8f80e3f35f61,failed,0,0,0,2025-08-14T08:48:38.249393,2025-08-14T08:49:00.740322,"66 Tran VT, Perrodeau E, Saldanha J, Pane I, Ravaud P. Efficacy of first dose of covid-19 vaccine
versus no vaccination on symptoms of patients with long covid: target trial emulation based on

ComPaRe e-cohort. BMJ Med. 2023;2(1):e000229. Published 2023 Feb 1. doi:10.1136/bmjmed-
2022-000229

67 Centers for Disease Control and Prevention Overview of COVID-19 Vaccines. [(accessed on 22
August 2023)]; Available online: https://www.cdc.gov/coronavirus/2019-
ncov/vaccines/different-vaccines/overview-COVID-19-vaccines.html
68 Porter NS, Jason LA, et al. Alternative Medical Interventions Used in the Treatment and
Management of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Fibromyalgia; J
Alternative and Complementary Medicine, 2010; 16:3, 235-249.
69 Mojaverrostami S, Bojnordi MN, et al., A Review of Herbal Therapy in Multiple Sclerosis. Adv
Pharm Bull. 2018;8(4):575-590. doi:10.15171/apb.2018.066.
70 Crabtree-Hartman E, Advanced Symptom Management in Multiple Sclerosis, Neurologic Clinics,
2018, Volume 36 (1), 197-218; https://doi.org/10.1016/j.ncl.2017.08.015.
71 Social Security Administration. Code of Federal Regulations: PART 404—FEDERAL OLD-AGE,
SURVIVORS AND DISABILITY INSURANCE (1950– ); U.S. Social Security Administration,
Revised as of April 1, 2023; accessed via https://www.ssa.gov/OP_Home/cfr20/404/404-
0000.htm) on August 4, 2024.
72 Grach SL, Seltzer J, Chon TY, Ganesh R. Diagnosis and Management of Myalgic
Encephalomyelitis/Chronic Fatigue Syndrome. Mayo Clin Proc. 2023;98(10):1544-1551.
doi:10.1016/j.mayocp.2023.07.032
73 Frieri M. Mast Cell Activation Syndrome. Clin Rev Allergy Immunol. 2018;54(3):353-365.
doi:10.1007/s12016-015-8487-6
74 Whitehead L. The measurement of fatigue in chronic illness: a systematic review of
unidimensional and multidimensional fatigue measures. J Pain Symptom Manage.
2009;37(1):107-128. doi:10.1016/j.jpainsymman.2007.08.019

75 Kuut TA, Müller F, Csorba I, Braamse A, Aldenkamp A, Appelman B, et al. Efficacy of Cognitive-
Behavioral Therapy Targeting Severe Fatigue Following Coronavirus Disease 2019: Results of a

Randomized Controlled Trial. Clinical Infectious Diseases. 2023;77(5):687-95
76 U.S. ME/CFS Clinician Coalition. Diagnosing and treating myalgic encephalomyelitis/chronic

fatigue syndrome (ME/CFS). July 2020. Accessed via https://mecfscliniciancoalition.org/wp-
content/uploads/2021/06/MECFS-Clinician-Coalition-Diagnosis-and-Treatment-Handout-V2.pdf

on August 4, 2024.
77 Singh SJ, Baldwin MM, Daynes E, et al. Respiratory sequelae of COVID-19: pulmonary and
extrapulmonary origins, and approaches to clinical care and rehabilitation. Lancet Respir Med.
2023;11(8):709-725. doi:10.1016/S2213-2600(23)00159-5
78 Frizzelli A, Di Spigno F, Moderato L, et al. An Impairment in Resting and Exertional Breathing
Pattern May Occur in Long-COVID Patients with Normal Spirometry and Unexplained Dyspnoea.
J Clin Med. 2022;11(24):7388. Published 2022 Dec 13. doi:10.3390/jcm11247388
79 Centers for Medicare and Medicaid Services. Billing and Coding: Pulmonary Rehabilitation

Services: A52770; October 1, 2023; accessed via https://www.cms.gov/medicare-coverage-
database/view/article.aspx?articleid=52770 on May 13, 2024.

80 Daynes E, Mills G, Hull JH, et al. Pulmonary Rehabilitation for People With Persistent Symptoms
After COVID-19. Chest. Published online January 19, 2024. doi:10.1016/j.chest.2024.01.029
81 Moine E, Molinier V, Castanyer A, et al. Safety and Efficacy of Pulmonary Rehabilitation for Long
COVID Patients Experiencing Long-Lasting Symptoms. Int J Environ Res Public Health.
2024;21(2):242. Published 2024 Feb 19. doi:10.3390/ijerph21020242

82 Meléndez-Oliva E, Martínez-Pozas O, Cuenca-Zaldívar JN, Villafañe JH, Jiménez-Ortega L,
Sánchez-Romero EA. Efficacy of Pulmonary Rehabilitation in Post-COVID-19: A Systematic
Review and Meta-Analysis. Biomedicines. 2023;11(8):2213. Published 2023 Aug 7.
doi:10.3390/biomedicines11082213"
7b36cbd0-4b42-48bd-8507-38bb5b8cd4d3,failed,0,0,0,2025-08-14T08:56:31.787810,2025-08-14T08:56:32.149686,"66 Tran VT, Perrodeau E, Saldanha J, Pane I, Ravaud P. Efficacy of first dose of covid-19 vaccine
versus no vaccination on symptoms of patients with long covid: target trial emulation based on

ComPaRe e-cohort. BMJ Med. 2023;2(1):e000229. Published 2023 Feb 1. doi:10.1136/bmjmed-
2022-000229

67 Centers for Disease Control and Prevention Overview of COVID-19 Vaccines. [(accessed on 22
August 2023)]; Available online: https://www.cdc.gov/coronavirus/2019-
ncov/vaccines/different-vaccines/overview-COVID-19-vaccines.html"
f358636d-1f68-44f7-bbbe-2c2c2c0fa3ac,completed,1,1,0,2025-08-14T08:59:24.621114,2025-08-14T08:59:32.238159,"66 Tran VT, Perrodeau E, Saldanha J, Pane I, Ravaud P. Efficacy of first dose of covid-19 vaccine versus no vaccination on symptoms of patients with long covid: target trial emulation based on ComPaRe e-cohort. BMJ Med. 2023;2(1):e000229. Published 2023 Feb 1. doi:10.1136/bmjmed-2022-000229"
039d443e-338f-43c6-a93f-ca23a5e4ad1c,failed,0,0,0,2025-08-14T09:29:24.915263,2025-08-14T09:29:42.568718,"66 Tran VT, Perrodeau E, Saldanha J, Pane I, Ravaud P. Efficacy of first dose of covid-19 vaccine
versus no vaccination on symptoms of patients with long covid: target trial emulation based on

ComPaRe e-cohort. BMJ Med. 2023;2(1):e000229. Published 2023 Feb 1. doi:10.1136/bmjmed-
2022-000229

67 Centers for Disease Control and Prevention Overview of COVID-19 Vaccines. [(accessed on 22
August 2023)]; Available online: https://www.cdc.gov/coronavirus/2019-
ncov/vaccines/different-vaccines/overview-COVID-19-vaccines.html
68 Porter NS, Jason LA, et al. Alternative Medical Interventions Used in the Treatment and
Management of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Fibromyalgia; J
Alternative and Complementary Medicine, 2010; 16:3, 235-249.
69 Mojaverrostami S, Bojnordi MN, et al., A Review of Herbal Therapy in Multiple Sclerosis. Adv
Pharm Bull. 2018;8(4):575-590. doi:10.15171/apb.2018.066.
70 Crabtree-Hartman E, Advanced Symptom Management in Multiple Sclerosis, Neurologic Clinics,
2018, Volume 36 (1), 197-218; https://doi.org/10.1016/j.ncl.2017.08.015.
71 Social Security Administration. Code of Federal Regulations: PART 404—FEDERAL OLD-AGE,
SURVIVORS AND DISABILITY INSURANCE (1950– ); U.S. Social Security Administration,
Revised as of April 1, 2023; accessed via https://www.ssa.gov/OP_Home/cfr20/404/404-
0000.htm) on August 4, 2024.
72 Grach SL, Seltzer J, Chon TY, Ganesh R. Diagnosis and Management of Myalgic
Encephalomyelitis/Chronic Fatigue Syndrome. Mayo Clin Proc. 2023;98(10):1544-1551.
doi:10.1016/j.mayocp.2023.07.032
73 Frieri M. Mast Cell Activation Syndrome. Clin Rev Allergy Immunol. 2018;54(3):353-365.
doi:10.1007/s12016-015-8487-6
74 Whitehead L. The measurement of fatigue in chronic illness: a systematic review of
unidimensional and multidimensional fatigue measures. J Pain Symptom Manage.
2009;37(1):107-128. doi:10.1016/j.jpainsymman.2007.08.019

75 Kuut TA, Müller F, Csorba I, Braamse A, Aldenkamp A, Appelman B, et al. Efficacy of Cognitive-
Behavioral Therapy Targeting Severe Fatigue Following Coronavirus Disease 2019: Results of a

Randomized Controlled Trial. Clinical Infectious Diseases. 2023;77(5):687-95
76 U.S. ME/CFS Clinician Coalition. Diagnosing and treating myalgic encephalomyelitis/chronic

fatigue syndrome (ME/CFS). July 2020. Accessed via https://mecfscliniciancoalition.org/wp-
content/uploads/2021/06/MECFS-Clinician-Coalition-Diagnosis-and-Treatment-Handout-V2.pdf

on August 4, 2024.
77 Singh SJ, Baldwin MM, Daynes E, et al. Respiratory sequelae of COVID-19: pulmonary and
extrapulmonary origins, and approaches to clinical care and rehabilitation. Lancet Respir Med.
2023;11(8):709-725. doi:10.1016/S2213-2600(23)00159-5
78 Frizzelli A, Di Spigno F, Moderato L, et al. An Impairment in Resting and Exertional Breathing
Pattern May Occur in Long-COVID Patients with Normal Spirometry and Unexplained Dyspnoea.
J Clin Med. 2022;11(24):7388. Published 2022 Dec 13. doi:10.3390/jcm11247388
79 Centers for Medicare and Medicaid Services. Billing and Coding: Pulmonary Rehabilitation

Services: A52770; October 1, 2023; accessed via https://www.cms.gov/medicare-coverage-
database/view/article.aspx?articleid=52770 on May 13, 2024.

80 Daynes E, Mills G, Hull JH, et al. Pulmonary Rehabilitation for People With Persistent Symptoms
After COVID-19. Chest. Published online January 19, 2024. doi:10.1016/j.chest.2024.01.029
81 Moine E, Molinier V, Castanyer A, et al. Safety and Efficacy of Pulmonary Rehabilitation for Long
COVID Patients Experiencing Long-Lasting Symptoms. Int J Environ Res Public Health.
2024;21(2):242. Published 2024 Feb 19. doi:10.3390/ijerph21020242

82 Meléndez-Oliva E, Martínez-Pozas O, Cuenca-Zaldívar JN, Villafañe JH, Jiménez-Ortega L,
Sánchez-Romero EA. Efficacy of Pulmonary Rehabilitation in Post-COVID-19: A Systematic
Review and Meta-Analysis. Biomedicines. 2023;11(8):2213. Published 2023 Aug 7.
doi:10.3390/biomedicines11082213"
7c261ca6-0447-4ede-8572-86251b220439,completed,3,3,0,2025-08-14T09:34:18.941135,2025-08-14T09:34:53.346553,"66 Tran VT, Perrodeau E, Saldanha J, Pane I, Ravaud P. Efficacy of first dose of covid-19 vaccine
versus no vaccination on symptoms of patients with long covid: target trial emulation based on

ComPaRe e-cohort. BMJ Med. 2023;2(1):e000229. Published 2023 Feb 1. doi:10.1136/bmjmed-
2022-000229

67 Centers for Disease Control and Prevention Overview of COVID-19 Vaccines. [(accessed on 22
August 2023)]; Available online: https://www.cdc.gov/coronavirus/2019-
ncov/vaccines/different-vaccines/overview-COVID-19-vaccines.html
68 Porter NS, Jason LA, et al. Alternative Medical Interventions Used in the Treatment and
Management of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Fibromyalgia; J
Alternative and Complementary Medicine, 2010; 16:3, 235-249."
a176aad5-bda7-43ed-b281-9491ed88e14a,processing,0,0,0,2025-08-14T09:35:50.634600,2025-08-14T09:35:50.647956,"66 Tran VT, Perrodeau E, Saldanha J, Pane I, Ravaud P. Efficacy of first dose of covid-19 vaccine
versus no vaccination on symptoms of patients with long covid: target trial emulation based on

ComPaRe e-cohort. BMJ Med. 2023;2(1):e000229. Published 2023 Feb 1. doi:10.1136/bmjmed-
2022-000229

67 Centers for Disease Control and Prevention Overview of COVID-19 Vaccines. [(accessed on 22
August 2023)]; Available online: https://www.cdc.gov/coronavirus/2019-
ncov/vaccines/different-vaccines/overview-COVID-19-vaccines.html
68 Porter NS, Jason LA, et al. Alternative Medical Interventions Used in the Treatment and
Management of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Fibromyalgia; J
Alternative and Complementary Medicine, 2010; 16:3, 235-249.
69 Mojaverrostami S, Bojnordi MN, et al., A Review of Herbal Therapy in Multiple Sclerosis. Adv
Pharm Bull. 2018;8(4):575-590. doi:10.15171/apb.2018.066.
70 Crabtree-Hartman E, Advanced Symptom Management in Multiple Sclerosis, Neurologic Clinics,
2018, Volume 36 (1), 197-218; https://doi.org/10.1016/j.ncl.2017.08.015.
71 Social Security Administration. Code of Federal Regulations: PART 404—FEDERAL OLD-AGE,
SURVIVORS AND DISABILITY INSURANCE (1950– ); U.S. Social Security Administration,
Revised as of April 1, 2023; accessed via https://www.ssa.gov/OP_Home/cfr20/404/404-
0000.htm) on August 4, 2024.
72 Grach SL, Seltzer J, Chon TY, Ganesh R. Diagnosis and Management of Myalgic
Encephalomyelitis/Chronic Fatigue Syndrome. Mayo Clin Proc. 2023;98(10):1544-1551.
doi:10.1016/j.mayocp.2023.07.032
73 Frieri M. Mast Cell Activation Syndrome. Clin Rev Allergy Immunol. 2018;54(3):353-365.
doi:10.1007/s12016-015-8487-6
74 Whitehead L. The measurement of fatigue in chronic illness: a systematic review of
unidimensional and multidimensional fatigue measures. J Pain Symptom Manage.
2009;37(1):107-128. doi:10.1016/j.jpainsymman.2007.08.019

75 Kuut TA, Müller F, Csorba I, Braamse A, Aldenkamp A, Appelman B, et al. Efficacy of Cognitive-
Behavioral Therapy Targeting Severe Fatigue Following Coronavirus Disease 2019: Results of a

Randomized Controlled Trial. Clinical Infectious Diseases. 2023;77(5):687-95
76 U.S. ME/CFS Clinician Coalition. Diagnosing and treating myalgic encephalomyelitis/chronic

fatigue syndrome (ME/CFS). July 2020. Accessed via https://mecfscliniciancoalition.org/wp-
content/uploads/2021/06/MECFS-Clinician-Coalition-Diagnosis-and-Treatment-Handout-V2.pdf

on August 4, 2024.
77 Singh SJ, Baldwin MM, Daynes E, et al. Respiratory sequelae of COVID-19: pulmonary and
extrapulmonary origins, and approaches to clinical care and rehabilitation. Lancet Respir Med.
2023;11(8):709-725. doi:10.1016/S2213-2600(23)00159-5
78 Frizzelli A, Di Spigno F, Moderato L, et al. An Impairment in Resting and Exertional Breathing
Pattern May Occur in Long-COVID Patients with Normal Spirometry and Unexplained Dyspnoea.
J Clin Med. 2022;11(24):7388. Published 2022 Dec 13. doi:10.3390/jcm11247388
79 Centers for Medicare and Medicaid Services. Billing and Coding: Pulmonary Rehabilitation

Services: A52770; October 1, 2023; accessed via https://www.cms.gov/medicare-coverage-
database/view/article.aspx?articleid=52770 on May 13, 2024.

80 Daynes E, Mills G, Hull JH, et al. Pulmonary Rehabilitation for People With Persistent Symptoms
After COVID-19. Chest. Published online January 19, 2024. doi:10.1016/j.chest.2024.01.029
81 Moine E, Molinier V, Castanyer A, et al. Safety and Efficacy of Pulmonary Rehabilitation for Long
COVID Patients Experiencing Long-Lasting Symptoms. Int J Environ Res Public Health.
2024;21(2):242. Published 2024 Feb 19. doi:10.3390/ijerph21020242

82 Meléndez-Oliva E, Martínez-Pozas O, Cuenca-Zaldívar JN, Villafañe JH, Jiménez-Ortega L,
Sánchez-Romero EA. Efficacy of Pulmonary Rehabilitation in Post-COVID-19: A Systematic
Review and Meta-Analysis. Biomedicines. 2023;11(8):2213. Published 2023 Aug 7.
doi:10.3390/biomedicines11082213"
101f418a-d81b-4acf-b544-e706a405c9a5,failed,0,0,0,2025-08-14T09:37:06.549550,2025-08-14T09:37:25.289739,"66 Tran VT, Perrodeau E, Saldanha J, Pane I, Ravaud P. Efficacy of first dose of covid-19 vaccine
versus no vaccination on symptoms of patients with long covid: target trial emulation based on

ComPaRe e-cohort. BMJ Med. 2023;2(1):e000229. Published 2023 Feb 1. doi:10.1136/bmjmed-
2022-000229

67 Centers for Disease Control and Prevention Overview of COVID-19 Vaccines. [(accessed on 22
August 2023)]; Available online: https://www.cdc.gov/coronavirus/2019-
ncov/vaccines/different-vaccines/overview-COVID-19-vaccines.html
68 Porter NS, Jason LA, et al. Alternative Medical Interventions Used in the Treatment and
Management of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Fibromyalgia; J
Alternative and Complementary Medicine, 2010; 16:3, 235-249.
69 Mojaverrostami S, Bojnordi MN, et al., A Review of Herbal Therapy in Multiple Sclerosis. Adv
Pharm Bull. 2018;8(4):575-590. doi:10.15171/apb.2018.066.
70 Crabtree-Hartman E, Advanced Symptom Management in Multiple Sclerosis, Neurologic Clinics,
2018, Volume 36 (1), 197-218; https://doi.org/10.1016/j.ncl.2017.08.015.
71 Social Security Administration. Code of Federal Regulations: PART 404—FEDERAL OLD-AGE,
SURVIVORS AND DISABILITY INSURANCE (1950– ); U.S. Social Security Administration,
Revised as of April 1, 2023; accessed via https://www.ssa.gov/OP_Home/cfr20/404/404-
0000.htm) on August 4, 2024.
72 Grach SL, Seltzer J, Chon TY, Ganesh R. Diagnosis and Management of Myalgic
Encephalomyelitis/Chronic Fatigue Syndrome. Mayo Clin Proc. 2023;98(10):1544-1551.
doi:10.1016/j.mayocp.2023.07.032
73 Frieri M. Mast Cell Activation Syndrome. Clin Rev Allergy Immunol. 2018;54(3):353-365.
doi:10.1007/s12016-015-8487-6
74 Whitehead L. The measurement of fatigue in chronic illness: a systematic review of
unidimensional and multidimensional fatigue measures. J Pain Symptom Manage.
2009;37(1):107-128. doi:10.1016/j.jpainsymman.2007.08.019

75 Kuut TA, Müller F, Csorba I, Braamse A, Aldenkamp A, Appelman B, et al. Efficacy of Cognitive-
Behavioral Therapy Targeting Severe Fatigue Following Coronavirus Disease 2019: Results of a

Randomized Controlled Trial. Clinical Infectious Diseases. 2023;77(5):687-95
76 U.S. ME/CFS Clinician Coalition. Diagnosing and treating myalgic encephalomyelitis/chronic

fatigue syndrome (ME/CFS). July 2020. Accessed via https://mecfscliniciancoalition.org/wp-
content/uploads/2021/06/MECFS-Clinician-Coalition-Diagnosis-and-Treatment-Handout-V2.pdf

on August 4, 2024.
77 Singh SJ, Baldwin MM, Daynes E, et al. Respiratory sequelae of COVID-19: pulmonary and
extrapulmonary origins, and approaches to clinical care and rehabilitation. Lancet Respir Med.
2023;11(8):709-725. doi:10.1016/S2213-2600(23)00159-5
78 Frizzelli A, Di Spigno F, Moderato L, et al. An Impairment in Resting and Exertional Breathing
Pattern May Occur in Long-COVID Patients with Normal Spirometry and Unexplained Dyspnoea.
J Clin Med. 2022;11(24):7388. Published 2022 Dec 13. doi:10.3390/jcm11247388
79 Centers for Medicare and Medicaid Services. Billing and Coding: Pulmonary Rehabilitation

Services: A52770; October 1, 2023; accessed via https://www.cms.gov/medicare-coverage-
database/view/article.aspx?articleid=52770 on May 13, 2024.

80 Daynes E, Mills G, Hull JH, et al. Pulmonary Rehabilitation for People With Persistent Symptoms
After COVID-19. Chest. Published online January 19, 2024. doi:10.1016/j.chest.2024.01.029
81 Moine E, Molinier V, Castanyer A, et al. Safety and Efficacy of Pulmonary Rehabilitation for Long
COVID Patients Experiencing Long-Lasting Symptoms. Int J Environ Res Public Health.
2024;21(2):242. Published 2024 Feb 19. doi:10.3390/ijerph21020242

82 Meléndez-Oliva E, Martínez-Pozas O, Cuenca-Zaldívar JN, Villafañe JH, Jiménez-Ortega L,
Sánchez-Romero EA. Efficacy of Pulmonary Rehabilitation in Post-COVID-19: A Systematic
Review and Meta-Analysis. Biomedicines. 2023;11(8):2213. Published 2023 Aug 7.
doi:10.3390/biomedicines11082213"
0e3bf8af-eeb7-4326-8e18-c5d6a1ec6f14,completed,5,5,0,2025-08-14T09:38:11.990407,2025-08-14T09:38:51.383560,"66 Tran VT, Perrodeau E, Saldanha J, Pane I, Ravaud P. Efficacy of first dose of covid-19 vaccine
versus no vaccination on symptoms of patients with long covid: target trial emulation based on

ComPaRe e-cohort. BMJ Med. 2023;2(1):e000229. Published 2023 Feb 1. doi:10.1136/bmjmed-
2022-000229

67 Centers for Disease Control and Prevention Overview of COVID-19 Vaccines. [(accessed on 22
August 2023)]; Available online: https://www.cdc.gov/coronavirus/2019-
ncov/vaccines/different-vaccines/overview-COVID-19-vaccines.html
68 Porter NS, Jason LA, et al. Alternative Medical Interventions Used in the Treatment and
Management of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Fibromyalgia; J
Alternative and Complementary Medicine, 2010; 16:3, 235-249.
69 Mojaverrostami S, Bojnordi MN, et al., A Review of Herbal Therapy in Multiple Sclerosis. Adv
Pharm Bull. 2018;8(4):575-590. doi:10.15171/apb.2018.066.
70 Crabtree-Hartman E, Advanced Symptom Management in Multiple Sclerosis, Neurologic Clinics,
2018, Volume 36 (1), 197-218; https://doi.org/10.1016/j.ncl.2017.08.015."
bf984b20-e36b-4bcf-b18a-38cb2bc76712,completed,7,6,1,2025-08-14T09:39:25.038300,2025-08-14T09:40:21.563263,"71 Social Security Administration. Code of Federal Regulations: PART 404—FEDERAL OLD-AGE,
SURVIVORS AND DISABILITY INSURANCE (1950– ); U.S. Social Security Administration,
Revised as of April 1, 2023; accessed via https://www.ssa.gov/OP_Home/cfr20/404/404-
0000.htm) on August 4, 2024.
72 Grach SL, Seltzer J, Chon TY, Ganesh R. Diagnosis and Management of Myalgic
Encephalomyelitis/Chronic Fatigue Syndrome. Mayo Clin Proc. 2023;98(10):1544-1551.
doi:10.1016/j.mayocp.2023.07.032
73 Frieri M. Mast Cell Activation Syndrome. Clin Rev Allergy Immunol. 2018;54(3):353-365.
doi:10.1007/s12016-015-8487-6
74 Whitehead L. The measurement of fatigue in chronic illness: a systematic review of
unidimensional and multidimensional fatigue measures. J Pain Symptom Manage.
2009;37(1):107-128. doi:10.1016/j.jpainsymman.2007.08.019

75 Kuut TA, Müller F, Csorba I, Braamse A, Aldenkamp A, Appelman B, et al. Efficacy of Cognitive-
Behavioral Therapy Targeting Severe Fatigue Following Coronavirus Disease 2019: Results of a

Randomized Controlled Trial. Clinical Infectious Diseases. 2023;77(5):687-95
76 U.S. ME/CFS Clinician Coalition. Diagnosing and treating myalgic encephalomyelitis/chronic

fatigue syndrome (ME/CFS). July 2020. Accessed via https://mecfscliniciancoalition.org/wp-
content/uploads/2021/06/MECFS-Clinician-Coalition-Diagnosis-and-Treatment-Handout-V2.pdf

on August 4, 2024.
77 Singh SJ, Baldwin MM, Daynes E, et al. Respiratory sequelae of COVID-19: pulmonary and
extrapulmonary origins, and approaches to clinical care and rehabilitation. Lancet Respir Med.
2023;11(8):709-725. doi:10.1016/S2213-2600(23)00159-5"
42ac9ab3-956e-46c9-ab57-c73adac0b02a,completed,7,6,1,2025-08-14T09:40:54.139483,2025-08-14T09:41:52.723194,"78 Frizzelli A, Di Spigno F, Moderato L, et al. An Impairment in Resting and Exertional Breathing
Pattern May Occur in Long-COVID Patients with Normal Spirometry and Unexplained Dyspnoea.
J Clin Med. 2022;11(24):7388. Published 2022 Dec 13. doi:10.3390/jcm11247388
79 Centers for Medicare and Medicaid Services. Billing and Coding: Pulmonary Rehabilitation

Services: A52770; October 1, 2023; accessed via https://www.cms.gov/medicare-coverage-
database/view/article.aspx?articleid=52770 on May 13, 2024.

80 Daynes E, Mills G, Hull JH, et al. Pulmonary Rehabilitation for People With Persistent Symptoms
After COVID-19. Chest. Published online January 19, 2024. doi:10.1016/j.chest.2024.01.029
81 Moine E, Molinier V, Castanyer A, et al. Safety and Efficacy of Pulmonary Rehabilitation for Long
COVID Patients Experiencing Long-Lasting Symptoms. Int J Environ Res Public Health.
2024;21(2):242. Published 2024 Feb 19. doi:10.3390/ijerph21020242

82 Meléndez-Oliva E, Martínez-Pozas O, Cuenca-Zaldívar JN, Villafañe JH, Jiménez-Ortega L,
Sánchez-Romero EA. Efficacy of Pulmonary Rehabilitation in Post-COVID-19: A Systematic
Review and Meta-Analysis. Biomedicines. 2023;11(8):2213. Published 2023 Aug 7.
doi:10.3390/biomedicines11082213
83 Belli S, Prince I, Savio G, et al. Airway Clearance Techniques: The Right Choice for the Right
Patient. Front Med (Lausanne). 2021;8:544826. Published 2021 Feb 4.
doi:10.3389/fmed.2021.544826.
84 Basu-Ray I, Almaddah Nk, Adeboye A, et al. Cardiac Manifestations of Coronavirus (COVID-19)
[Updated 2024 Feb 12]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing;
2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK556152/"
0a669600-14c1-412d-bb07-6740cc18ae07,completed,6,6,0,2025-08-14T09:42:22.370036,2025-08-14T09:43:15.626259,"85 Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022
Mar;28(3):583-590. doi: 10.1038/s41591-022-01689-3. Epub 2022 Feb 7. PMID: 35132265;
PMCID: PMC8938267.
86 Tintore C, Cuartero J, Camps-Vilaró A, et al. Increased risk of arrhythmias, heart failure, and
thrombosis in SARS-CoV-2 positive individuals persists at one year post-infection. Comput
Struct Biotechnol J. 2024;24:476-483. Published 2024 Jun 20. doi:10.1016/j.csbj.2024.06.024
87 Writing Committee, Gluckman TJ, Bhave NM, et al. 2022 ACC Expert Consensus Decision
Pathway on Cardiovascular Sequelae of COVID-19 in Adults: Myocarditis and Other Myocardial
Involvement, Post-Acute Sequelae of SARS-CoV-2 Infection, and Return to Play: A Report of the
American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol.
2022;79(17):1717-1756. doi:10.1016/j.jacc.2022.02.003
88 Kuehn BM. Post-COVID Return to Play Guidance Evolves. Circulation. 2022;146(6):498-499.
doi:10.1161/CIRCULATIONAHA.122.060645
89 Salman D, Vishnubala D, Le Feuvre P, et al. Returning to physical activity after covid-19. BMJ.
2021;372:m4721. Published 2021 Jan 8. doi:10.1136/bmj.m4721
90 Vernino S, Hopkins S, Bryarly M, Hernandez RS, Salter A. Randomized controlled trial of
intravenous immunoglobulin for autoimmune postural orthostatic tachycardia syndrome
(iSTAND). Clin Auton Res. 2024;34(1):153-163. doi:10.1007/s10286-024-01020-9"
013f5621-6d95-4d4b-9d41-83124f23990b,completed,6,5,1,2025-08-14T09:43:56.351744,2025-08-14T09:44:45.997543,"91 Dysautonomia Support Network. COUNTER-PRESSURE MANEUVERS. 2021; accessed via
https://www.dysautonomiasupport.org/counter-pressure-maneuvers/ on May 20, 2024.
92 Becker JH, Lin JJ, Twumasi A, et al. Greater executive dysfunction in patients post-COVID-19
compared to those not infected. Brain Behav Immun. 2023;114:111-117.
doi:10.1016/j.bbi.2023.08.014
93 Substance Abuse and Mental Health Services Administration. Identification and Management of
Mental Health Symptoms and Conditions Associated with Long COVID. Publication No. PEP23-
06-05-007. Rockville, MD: National Mental Health and Substance Use Policy Laboratory,
Substance Abuse and Mental Health Services Administration, 2023.
94 Perez Giraldo GS, Ali ST, Kang AK, et al. Neurologic Manifestations of Long COVID Differ Based
on Acute COVID-19 Severity. Ann Neurol. 2023;94(1):146-159. doi:10.1002/ana.26649
95 Aziz R, Siles N, Kelley M, Wylie D, Melamed E, Brode WM. Clinical characteristics of Long COVID
patients presenting to a dedicated academic post-COVID-19 clinic in Central Texas. Sci Rep.
2023;13(1):21971. Published 2023 Dec 11. doi:10.1038/s41598-023-48502-w
96 Ozonoff A, Jayavelu ND, Liu S, et al. Features of acute COVID-19 associated with post-acute
sequelae of SARS-CoV-2 phenotypes: results from the IMPACC study. Nat Commun.
2024;15(1):216. Published 2024 Jan 3. doi:10.1038/s41467-023-44090-5"
b1083883-de61-4d06-9cbc-3523f6cdf9b8,completed,6,5,1,2025-08-14T09:46:15.597141,2025-08-14T09:48:21.769444,"97 Reis, G. A Multicenter, Adaptive, Randomized, doublE-blinded, Placebo-controlled Study in
Participants With Long COVID-19: The REVIVE Trial (REVIVE); ClinicalTrials.gov ID NCT06128967.
Updated November 13, 2023. Accessed August 4, 204 via
https://clinicaltrials.gov/study/NCT06128967?cond=long%20covid&intr=metformin&rank=2.
98 Lenze E. Fluvoxamine for Long COVID-19; ClinicalTrials.gov ID NCT05874037; Updated August
14, 2023. Accessed August 4, 2024 via https://clinicaltrials.gov/study/NCT05874037.

99 Hurt RT, Yadav S, Schroeder DR, et al. Longitudinal Progression of Patients with Long COVID
Treated in a Post-COVID Clinic: A Cross-Sectional Survey. J Prim Care Community Health.
2024;15:21501319241258671. doi:10.1177/21501319241258671
100 Sathyamoorthy M, Verduzco-Gutierrez M, Varanasi S, Ward R, Spertus J, Shah S. Enhanced
external counterpulsation for management of symptoms associated with long COVID. Am Heart
J Plus. 2022;13:100105. Published 2022 Feb 12. doi:10.1016/j.ahjo.2022.100105
101 Fox J, Verduzco-Gutierrez M, Sanchez S, et al. Enhanced External Counterpulsation Improves
Long COVID-Associated Symptoms. Am J Cardiol. 2024;224:12-13.
doi:10.1016/j.amjcard.2024.05.037
102 Sathyamoorthy M, Sevak RJ, Cabrera J, et al. Enhanced External Counterpulsation Improves
Cognitive Function of Persons With Long COVID. Am J Phys Med Rehabil. 2024;103(8):734-739.
doi:10.1097/PHM.0000000000002433"
4ff58089-2f2c-454b-b25e-cc569f4243b3,completed,6,6,0,2025-08-14T10:06:27.390555,2025-08-14T10:07:14.805675,"103 Kalava A, Benyahia SA, Tico Calzada R, Staat CM. Efficacy of Stellate Ganglion Block in Treating
Long-Term COVID-19-Related Olfactory and Gustatory Dysfunction: A Case Series. Cureus.
2023;15(6):e40929. Published 2023 Jun 25. doi:10.7759/cureus.40929
104 Khan MH, Kirkpatrick KP, Deng Y, Shah KB. Stellate Ganglion Block for Long COVID Symptom
Management: A Case Report. Cureus. 2022;14(12):e32295. Published 2022 Dec 7.
doi:10.7759/cureus.32295
105 Pearson L, Maina A, Compratt T, et al. Stellate Ganglion Block Relieves Long COVID-19
Symptoms in 86% of Patients: A Retrospective Cohort Study. Cureus. 2023;15(9):e45161.
Published 2023 Sep 13. doi:10.7759/cureus.45161
106 Chakraborty P, Farhat K, Morris L, Whyte S, Yu X, Stavrakis S. Non-invasive Vagus Nerve
Simulation in Postural Orthostatic Tachycardia Syndrome. Arrhythm Electrophysiol Rev.
2023;12:e31. Published 2023 Dec 13. doi:10.15420/aer.2023.20
107 Zheng ZS, Simonian N, Wang J, Rosario ER. Transcutaneous vagus nerve stimulation improves
Long COVID symptoms in a female cohort: a pilot study. Front Neurol. 2024;15:1393371.
Published 2024 May 2. doi:10.3389/fneur.2024.1393371
108 Wu BQ, Liu DY, Shen TC, et al. Effects of Hyperbaric Oxygen Therapy on Long COVID: A
Systematic Review. Life (Basel). 2024;14(4):438. Published 2024 Mar 26.
doi:10.3390/life14040438"
3541dac3-0170-446c-a600-b06a07ef0212,completed,5,4,1,2025-08-14T10:07:46.864022,2025-08-14T10:08:41.278917,"109 Linnhoff S, Koehler L, Haghikia A, Zaehle T. The therapeutic potential of non-invasive brain
stimulation for the treatment of Long-COVID-related cognitive fatigue. Front Immunol.
2023;13:935614. Published 2023 Jan 9. doi:10.3389/fimmu.2022.935614
110 Klírová M, Adamová A, Biačková N, et al. Transcranial direct current stimulation (tDCS) in the
treatment of neuropsychiatric symptoms of long COVID. Sci Rep. 2024;14(1):2193. Published
2024 Jan 25. doi:10.1038/s41598-024-52763-4
111 Zimmerman K, Laskowitz, D. RECOVER-NEURO: Platform Protocol, Appendix_A to Measure the
Effects of BrainHQ, PASC CoRE and tDCS Interventions on Long COVID Symptoms.
ClinicalTrials.gov ID NCT05965739. Updated June 18, 2024. Accessed August 4, 2024.
https://clinicaltrials.gov/study/NCT05965739?term=recover-neuro&rank=3
112 Steffen PR, Austin T, DeBarros A, Brown T. The Impact of Resonance Frequency Breathing on
Measures of Heart Rate Variability, Blood Pressure, and Mood. Front Public Health. 2017;5:222.
Published 2017 Aug 25. doi:10.3389/fpubh.2017.00222
113 Chung AH, Gevirtz RN, Gharbo RS, Thiam MA, Ginsberg JPJ. Pilot Study on Reducing Symptoms
of Anxiety with a Heart Rate Variability Biofeedback Wearable and Remote Stress Management
Coach. Appl Psychophysiol Biofeedback. 2021;46(4):347-358. doi:10.1007/s10484-021-09519-x"
